Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus SONAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus SONAZINE.
MELLARIL vs SONAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Sonazine is an antipsychotic agent that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonist activity at D1, alpha1-adrenergic, histaminergic H1, and muscarinic M1 receptors.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Terminal elimination half-life: 24-36 hours; clinical context: allows once-daily dosing, steady state achieved in 5-7 days, prolongation in elderly or hepatic impairment
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via biliary elimination)
Category C
Category C
Antipsychotic
Antipsychotic